|
Title
|
|
|
|
Hepatitis A virus infection
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Hepatitis A is a vaccine-preventable infection caused by the hepatitis A virus (HAV). Over 150 million new infections of hepatitis A occur annually. HAV causes an acute inflammatory reaction in the liver that usually resolves spontaneously without chronic sequelae. However, up to 20% of patients experience a prolonged or relapsed course and <1% experience acute liver failure. Host factors, such as immunological status, age, pregnancy and underlying hepatic diseases, can affect the severity of disease. Anti-HAV IgG antibodies produced in response to HAV infection persist for life and protect against re-infection; vaccine-induced antibodies against hepatitis A confer long-term protection. The WHO recommends vaccination for individuals at higher risk of infection and/or severe disease in countries with very low and low hepatitis A virus endemicity, and universal childhood vaccination in intermediate endemicity countries. To date, >25 countries worldwide have implemented such programmes, resulting in a reduction in the incidence of HAV infection. Improving hygiene and sanitation, rapid identification of outbreaks and fast and accurate intervention in outbreak control are essential to reducing HAV transmission. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Nature reviews disease primers. - London, 2015, currens
| |
|
Publication
|
|
|
|
London
:
Nature Publishing Group
,
2023
| |
|
ISSN
|
|
|
|
2056-676X
| |
|
DOI
|
|
|
|
10.1038/S41572-023-00461-2
| |
|
Volume/pages
|
|
|
|
9
:1
(2023)
, p. 1-18
| |
|
Article Reference
|
|
|
|
51
| |
|
ISI
|
|
|
|
001091656300002
| |
|
Pubmed ID
|
|
|
|
37770459
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|